IP Library Granted Patent US 8,703,795
Granted Patent B2
US 8,703,795 · App. 11/367,969 · Granted Apr 22, 2014

Thienopyridine compounds, and methods of use thereof

Inventors: Eric D. Turtle (Belmont, CA); Lee A. Flippin (Woodside, CA); Michael P. Arend (Foster City, CA); Heng Cheng (Millbrae, CA)
Assignee: Fibrogen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,795
App. No.
11/367,969
Granted
Apr 22, 2014
Kind
B2
Abstract

The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).

Claims (93)

1. A compound of formula Ia:

wherein

q is 0 or 1;

R 1 is selected from the group consisting of hydroxy, alkoxy, substituted alkoxy, acyloxy, cycloalkoxy, substituted cycloalkoxy, aryloxy, substituted aryloxy, mercapto, thioether, amino, substituted amino, and aminoacyl;

R 2 is selected from the group consisting of hydrogen, deuterium, and methyl;

R 3 is selected from the group consisting of hydrogen, deuterium, alkyl, and R 101 ;

R 4 is selected from the group consisting of hydrogen, alkyl, and R 101 ;

R 5 is selected from the group consisting of hydrogen, halo, alkyl, R 101 , alkenyl, R 111 , alkynyl, R 113 alkoxy, substituted alkoxy, cycloalkyl, R 103 , cycloalkoxy, substituted cycloalkoxy, amino, substituted amino, aminoacyl, aryl, R 105 , aryloxy, substituted aryloxy, furanyl, thienyl, thioether, cyano, and acyl; and

R 6 and R 7 are independently selected from the group consisting of hydrogen, hydroxy, cyano, halo, nitro, acyl, amino, substituted amino, acylamino, sulfonyl, alkyl, R 101 , alkenyl, R 111 , alkynyl, R 113 alkoxy, substituted alkoxy, aryl, R 105 , aryloxy, substituted aryloxy, thioether, arylthio, and substituted arylthio;

or a pharmaceutically acceptable salt, single stereoisomer, or mixture of stereoisomers thereof, or an ester or amide of the —COOH group on the glycine- or alanine-based substituent of the thienopyridine ring, which ester is selected from —C(O)O-alkyl, —C(O)O—R 101 , —C(O)O-alkenyl, —C(O)O—R 111 , —C(O)O-alkynyl, —C(O)O—R 113 , —C(O)O-aryl, and —C(O)O—R 105 ; and the amide is derived from amines of the formula HNR 20 R 21 , where R 20 and R 21 are independently hydrogen, alkyl, R 101 , aryl, or R 105 ; and further wherein

R 101 is substituted alkyl, wherein substituted alkyl is alkyl having from 1 to 5 substituents selected from the group consisting of R 200 , R 201 , R 202 , and R 203 ;

R 103 is substituted cycloalkyl, wherein substituted cycloalkyl is cycloalkyl having from 3 to 10 carbon atoms having single or multiple cyclic rings and from 1 to 5 substituents selected from the group consisting of oxo (═O), thioxo (═S), alkyl, R 101 , and R 201 ;

R 105 is substituted aryl, wherein substituted aryl is aryl having from 1 to 4 substituents selected from the group consisting of R 201 , alkyl, R 101 , alkenyl, R 111 , alkynyl, R 113 , R 202 , R 203 , amidino, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, cycloalkoxy, substituted cycloalkoxy, thiol, alkylthio, substituted alkylthio, arylthio, substituted arylthio, cycloalkylthio, substituted cycloalkylthio, guanidino, oxycarbonylamino, oxythiocarbonylamino, —S(O) 2 -alkyl, —S(O) 2 —R 101 , —S(O) 2 -cycloalkyl, —S(O) 2 —R 103 , —S(O) 2 -alkenyl, —S(O) 2 —R 111 , —S(O) 2 -aryl, and —S(O) 2 —R 105 ;

R 111 is substituted alkenyl, wherein substituted alkenyl is alkenyl having from 1 to 3 R 201 ;

R 113 is substituted alkynyl, wherein substituted alkynyl is alkynyl having from 1 to 3 R 201 ;

R 200 is aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxyaryl, substituted aryloxyaryl, oxo, thioxo, thiol, alkylthio, substituted alkylthio, arylthio, substituted arylthio, cycloalkylthio, substituted cycloalkylthio, cycloalkoxy, substituted cycloalkoxy, oxycarbonylamino, and oxythiocarbonylamino;

R 201 is alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryloxy, substituted aryloxy, cyano, halogen, hydroxyl, nitro, carboxyl, carboxyl esters, cycloalkyl, R 103 , aryl, and R 105 ;

R 202 is —NR 40 S(O) 2 -alkyl, —NR 40 S(O) 2 —R 101 , —NR 40 S(O) 2 -aryl, —NR 40 S(O) 2 —R 105 , —NR 40 S(O) 2 —NR 40 -alkyl, —NR 40 S(O) 2 —NR 40 —R 101 , —NR 40 S(O) 2 —NR 40 -aryl, and —NR 40 S(O) 2 —NR 40 —R 105 , where each R 40 is hydrogen or alkyl; and

R 203 is —OS(O) 2 -alkyl, —OS(O) 2 —R 101 , —OS(O) 2 -aryl, —OS(O) 2 —R 105 , and —OSO 2 —NR 40 R 40 where each R 40 is hydrogen or alkyl;

and further wherein

substituted alkoxy is —O—R 101 ;

substituted cycloalkoxy is —O—R 103 ;

substituted aryloxy is —O—R 105 ;

substituted amino is —NR 41 R 41 , where each R 41 group is independently selected from the group consisting of hydrogen, alkyl, R 101 , alkenyl, R 111 , alkynyl, R 113 , cycloalkyl, R 103 , aryl, R 105 , —S(O) 2 -alkyl, —S(O) 2 —R 101 , —S(O) 2 -cycloalkyl, —S(O) 2 —R 103 , —S(O) 2 -alkenyl, —S(O) 2 —R 111 , —S(O) 2 -aryl, and —S(O) 2 —R 105 , provided that both R 41 groups are not hydrogen;

substituted alkylthio is —S—R 101 ;

substituted arylthio is —S—R 105 ;

substituted cycloalkylthio is —S—R 103 ;

substituted aryloxyaryl is aryl-O-aryl, wherein each aryl group is substituted on either or both aryl rings with from 1 to 3 substituents selected from the group consisting of R 201 , alkyl, R 101 , alkenyl, R 111 , alkynyl, R 113 , R 202 , R 203 , amidino, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, cycloalkoxy, substituted cycloalkoxy, thiol, alkylthio, substituted alkylthio, arylthio, substituted arylthio, cycloalkylthio, substituted cycloalkylthio, guanidino, oxycarbonylamino, oxythiocarbonylamino, —S(O) 2 -alkyl, —S(O) 2 —R 101 , —S(O) 2 -cycloalkyl, —S(O) 2 —R 103 , —S(O) 2 -alkenyl, —S(O) 2 —R 111 , —S(O) 2 -aryl, and —S(O) 2 —R 105 ; and

acyl is H—C(O)—, alkyl-C(O)—, R 101 —C(O)—, alkenyl-C(O)—, R 111 —C(O)—, alkynyl-C(O)—, R 113 —C(O)—, cycloalkyl-C(O)—, R 103 —C(O)—, aryl-C(O)—, or R 105 —C(O)—.

2. The compound of claim 1 , wherein q is 0.

3. The compound of claim 1 , wherein R 1 is hydroxy.

4. The compound of claim 3 , wherein R 2 , R 3 , and R 4 are all hydrogen.

5. The compound of claim 1 , wherein R 5 is selected from the group consisting of hydrogen, alkyl, halo, aryl, R 105 , cyano, alkynyl, furanyl, and thienyl.

6. The compound of claim 5 , wherein R 5 is selected from the group consisting of hydrogen, methyl, bromo, chloro, phenyl, fluorophenyl, cyano, ethynyl, furanyl, and thienyl.

7. The compound of claim 1 , wherein R 6 is selected from the group consisting of hydrogen, halo, alkyl, R 101 , alkenyl, R 111 , aryl, R 105 , aryloxy, arylthio, and cyano.

8. The compound of claim 7 , wherein R 6 is selected from the group consisting of hydrogen, bromo, methyl, phenyl, trifluoromethylphenyl, phenoxyphenyl, fluorophenyl, phenylsulfanyl, phenethyl, phenylethenyl, phenoxy, and cyano.

9. The compound of claim 1 , wherein R 7 is selected from the group consisting of hydrogen, aryl, and R 105 .

10. The compound of claim 1 , wherein R 7 is selected from the group consisting of hydrogen, phenyl, and fluorophenyl.

11. The compound of claim 1 , wherein

R 1 is hydroxy;

R 2 , R 3 , and R 4 are hydrogen;

R 5 is hydrogen, halo, alkyl, or aryl;

R 6 is hydrogen, halo, alkyl, R 101 , aryl, R 105 , arylthio, alkenyl, R 111 , or aryloxy; and

R 7 is hydrogen, aryl, or R 105 ;

or a pharmaceutically acceptable salt, single stereoisomer, or mixture of stereoisomers thereof, or an ester or amide of the —COOH group on the glycine- or alanine-based substituent of the thienopyridine ring, which ester is selected from —C(O)O-alkyl, —C(O)O—R 101 , —C(O)O-alkenyl, —C(O)O—R 111 , —C(O)O-alkynyl, —C(O)O—R 113 , —C(O)O-aryl, and —C(O)O—R 105 ; and the amide is derived from amines of the formula HNR 20 R 21 , where R 20 and R 21 are independently hydrogen, alkyl, R 101 , aryl, or R 105 .

12. The compound of claim 1 , wherein

R 1 is hydroxy;

R 2 , R 3 , and R 4 are hydrogen;

R 5 is halo, alkyl, alkynyl, cyano, aryl, R 105 , furanyl or thienyl;

R 6 is hydrogen, halo, alkyl, aryl, R 105 or cyano; and

R 7 is hydrogen, aryl, or R 105 ;

or a pharmaceutically acceptable salt, single stereoisomer, or mixture of stereoisomers thereof, or an ester or amide of the —COOH group on the glycine- or alanine-based substituent of the thienopyridine ring, which ester is selected from —C(O)O-alkyl, —C(O)O—R 101 , —C(O)O-alkenyl, —C(O)O—R 111 , —C(O)O-alkynyl, —C(O)O—R 113 , —C(O)O-aryl, and —C(O)O—R 105 ; and the amide is derived from amines of the formula HNR 20 R 21 , where R 20 and R 21 are independently hydrogen, alkyl, R 101 , aryl, or R 105 .

13. A compound of claim 1 , selected from the group consisting of:

[(2-Bromo-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

{[7-Hydroxy-2-(4-methoxy-phenyl)-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

[(7-Hydroxy-2,4-dimethyl-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

{[7-Hydroxy-4-methyl-2-(4-phenoxy-phenyl)-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[7-Hydroxy-2-(4-phenoxy-phenyl)-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

[(7-Hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(2-Bromo-4-chloro-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(2,4-Dibromo-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(7-Hydroxy-2-phenylsulfanyl-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(7-Hydroxy-2,4-diphenyl-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(7-Hydroxy-2-styryl-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(7-Hydroxy-2-phenoxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(7-Hydroxy-2-phenethyl-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

{[7-Hydroxy-2-(3-trifluoromethyl-phenyl)-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[4-Bromo-7-hydroxy-2-(3-trifluoromethyl-phenyl)-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[4-Cyano-7-hydroxy-2-(3-trifluoromethyl-phenyl)-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

[(2-Cyano-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

{[7-Hydroxy-2-(4-trifluoromethyl-phenyl)-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[7-Hydroxy-2-(2-trifluoromethyl-phenyl)-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[4-Bromo-3-(4-fluoro-phenyl)-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[3-(4-Fluoro-phenyl)-7-hydro-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[3-(4-Fluoro-phenyl)-7-hydroxy-4-methyl-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[4-Cyano-3-(4-fluoro-phenyl)-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[2-(4-fluoro-phenyl)-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[2-(4-fluoro-phenyl)-7-hydroxy-4-methyl-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

{[2,3-Bis-(4-fluoro-phenyl)-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

[(4-Chloro-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(4-Bromo-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(7-Hydroxy-4-phenyl-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

{[4-(4-Fluoro-phenyl)-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl]-amino}-acetic acid;

[(4-Furan-2-yl-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(4-Furan-3-yl-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(7-Hydroxy-4-thiophen-2-yl-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(7-Hydroxy-4-thiophen-3-yl-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(7-Hydroxy-4-methyl-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

[(4-Ethynyl-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

and

[(4-Cyano-7-hydroxy-thieno[3,2-c]pyridine-6-carbonyl)-amino]-acetic acid;

or a pharmaceutically acceptable salt, single stereoisomer, or mixture of stereoisomers thereof, or an ester or amide of the —COOH group on the glycine- or alanine-based substituent of the thienopyridine ring, which ester is selected from —C(O)O-alkyl, —C(O)O—R 101 , —C(O)O-alkenyl, —C(O)O—R 111 , —C(O)O-alkenyl, —C(O)O—R 113 , —C(O)O-aryl, and —C(O)O—R 105 ; and the amide is derived from amines of the formula HNR 20 R 21 , where R 20 and R 21 are independently hydrogen, alkyl, R 101 , aryl, or R 105 .

14. A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier, and a therapeutically effective amount of one or more compound as claimed in any one of claims 1 , 12 , and 13 .

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2006
From: TURTLE, ERIC D.; FLIPPIN, LEE A.; AREND, MICHAEL P.; CHENG, HENG
To: FIBROGEN, INC.
Reel/Frame 018566/0786 →
Continuity (2)
Provisional Application 60658131 · Mar 2, 2005
Related Publication 20060199836A1 · Sep 7, 2006